Crescent Biopharma
CBIO
47 hedge funds and large institutions have $64.9M invested in Crescent Biopharma in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 20 reducing their positions, and 15 closing their positions.
42% more call options, than puts
Call options by funds: $1.08M | Put options by funds: $763K
3.11% less ownership
Funds ownership: 60.65% → 57.53% (-3.1%)
19% less funds holding
Funds holding: 58 → 47 (-11)
55% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 20
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
69% less capital inflows, than outflows
Capital inflows: $1.45M | Capital outflows: $4.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$578K |
| 2 |
Franklin Resources
San Mateo,
California
|
+$340K |
| 3 |
VF
Virtu Financial
New York
|
+$115K |
| 4 |
D.E. Shaw & Co
New York
|
+$109K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$76.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$581K |
| 2 |
Millennium Management
New York
|
-$505K |
| 3 |
JP Morgan Chase
New York
|
-$494K |
| 4 |
E
Ergoteles
New York
|
-$373K |
| 5 |
Renaissance Technologies
New York
|
-$342K |
CBIO Hedge Fund Activity: Q3 2021 in Review
47 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2021, worth a combined $64.9M — down 10% from $72.5M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CBIO and 5 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 9 added.
The largest buyer was Two Sigma Investments, adding an estimated $578K. The largest seller was Dimensional Fund Advisors, cutting an estimated $581K.
- 47 institutional investors held Crescent Biopharma (CBIO) as of Q3 2021, down from 58 in Q2 2021.
- Funds reported $64.9M of Crescent Biopharma stock for Q3 2021, down 10% quarter-over-quarter.
- 5 funds opened new Crescent Biopharma positions in Q3 2021 and 15 closed out, a net change of -10 holders.
- The largest Crescent Biopharma buyer in Q3 2021 was Two Sigma Investments, an estimated $578K added.
- The largest Crescent Biopharma seller in Q3 2021 was Dimensional Fund Advisors, an estimated $581K sold.
Based on aggregated 13F filings for Q3 2021.